Cogent Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cogent Biosciences (COGT).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

1S.Buy

8Buy

3Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$38Upside to Avg. PT+35.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 16, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$55
Sep 15, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$55
Aug 17, 2026	Piper Sandler	Christopher Raymond	PT Raise	Overweight	$52→$55
Aug 12, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$45→$52
May 29, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$55
May 6, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$52→$55
Mar 17, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$55
Mar 16, 2026	Jefferies	Faisal Khurshid	Assumes	Buy	$55
Feb 18, 2026	Piper Sandler	Christopher Raymond	PT Raise	Overweight	$39→$52
Jan 21, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$55
Jan 6, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$50→$52
Dec 19, 2025	JP Morgan	Anupam Rama	PT Raise	Overweight	$65→$67
Dec 8, 2025	Needham	Ami Fadia	Maintained	Hold	—
Nov 13, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$21→$50
Nov 11, 2025	Baird	Colleen Kusy	PT Raise	Neutral	$14→$34
Nov 10, 2025	Leerink Partners	Andrew Berens	PT Raise	Outperform	$18→$50
Nov 4, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$21
Oct 21, 2025	JP Morgan	Anupam Rama	PT Raise	Overweight	$30→$44
Oct 16, 2025	Stifel	Laura Prendergast	Initiate	Hold	$16
Sep 3, 2025	Raymond James	Chris Raymond	Initiate	Strong Buy	$30

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $55 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55

HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $52 to $55.

Benzinga Newsdesk

Cogent Biosciences Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Cogent Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target

PRO
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

PRO
Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55

People Also Watch

People Also Watch

Cogent Biosciences Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Cogent Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

PROHC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target

PROPiper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

PROGuggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

PROWedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

PROHC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55

People Also Watch

People Also Watch

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target

PRO
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

PRO
Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55